Have a personal or library account? Click to login
Persistent Ductus Arteriosus in Critically Ill Preterm Infants Cover

Persistent Ductus Arteriosus in Critically Ill Preterm Infants

Open Access
|Nov 2016

References

  1. 1. Kaemmerer H, Meisner H, Hess J, Perloff JK. Surgical treatment of patent ductus arteriosus: a new historical perspective. Am J Cardiol. 2004;94:1153-4.10.1016/j.amjcard.2004.07.082
  2. 2. Schneider DJ, Moore JW. Patent Ductus Arteriosus. Circulation 2006;114:1873-82. DOI: 10.1161/CIRCULATIONAHA.105.592063.10.1161/CIRCULATIONAHA.105.592063
  3. 3. Hillman M, Meinarde L, Rizzotti A, Cuestas E. Inflammation, High-sensitivity C-reactive Protein, and Persistent Patent Ductus Arteriosus in Preterm Infants. Rev Esp Cardiol (Engl Ed). 2016;69:84-5. doi: 10.1016/j.rec.2015.09.014.10.1016/j.rec.2015.09.014
  4. 4. Al Nemri AMH. Patent ductus arteriosus in preterm infant: Basic pathology and when to treat. Sudan J Paediatr. 2014;14:25-30.
  5. 5. Abdel-Hady H, Nasef N, Shabaan AE, Nour I. Patent Ductus Arteriosus in Preterm Infants: Do We Have the Right Answers? BioMed Research International 2013. http://dx.doi.org/10.1155/2013/676192.
  6. 6. Dice JE, Bhatia J. Patent Ductus Arteriosus: An Overview. J Pediatr Pharmacol Ther. 2007;12:138-46. doi: 10.5863/1551-6776-12.3.13810.5863/1551-6776-12.3.138
  7. 7. Fanos V, Pusceddu M, Dessi A, Marcialis MA. Should we definitively abandon prophylaxis for patent ductus arteriosus in preterm new-borns? Clinics. 2011;66:2141-9. http://dx.doi.org/10.1590/S1807-59322011001200022.
  8. 8. Hermes-DeSantis ER, Clyman RI. Patent ductus arteriosus: pathophysiology and management. J Perinatol. 2006;26:S14-8. DOI: 10.1038/sj.jp.721146510.1038/sj.jp.7211465
  9. 9. Clyman RI. Ibuprofen and patent ductus arteriosus. N Engl J Med. 2000;343:728-39. DOI: 10.1056/NEJM20000907343100910.1056/NEJM200009073431009
  10. 10. Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol. 2002;39:1890-900.10.1016/S0735-1097(02)01886-7
  11. 11. Fortescue EB, Lock JE, Galvin T, McElhinney DB. To Close or Not to Close: The Very Small Patent Ductus Arteriosus. Congenit Heart Dis. 2010;5:354-65. doi: 10.1111/j.1747-0803.2010.00435.x.10.1111/j.1747-0803.2010.00435.x424022420653702
  12. 12. Toganel R. Critical Congenital Heart Diseases as Lifethreatening Conditions in the Emergency Room. Journal of Cardiovascular Emergencies. 2016;2:7-10. DOI: 10.1515/jce-2016-0002.10.1515/jce-2016-0002
  13. 13. Feng YS, Yu V. Management of Patent Ductus Arteriosus in Very Preterm Infants in the Post-surfactant Era. HK J Paediatr (new series). 2003;8:93-100.
  14. 14. Hammoud MS, Elsori HA, Hanafi E-AM, Shalabi AA, Fouda IA, Devarajan LV. Incidence and risk factors associated with the patency of ductus arteriosus inpreterm infants with respiratory distress syndrome in Kuwait. Saudi Med J. 2003;24:982-5.
  15. 15. Lee JA, Kim M-J, Oh S, Choi BM. Current Status of Therapeutic Strategies for Patent Ductus Arteriosus in Very-Low-Birth-Weight Infants in Korea. J Korean Med Sci. 2015;30:S59-66. doi: 10.3346/jkms.2015.30.S1.S59.10.3346/jkms.2015.30.S1.S59464106526566359
  16. 16. Nizarali Z, Marques T, Costa C, Barroso R, Cunha M. Patent Ductus Arteriosus: Perinatal Risk Factors. J Neonatal Biol. 2012;1:3. http://dx.doi.org/10.4172/2167-0897.1000109.
  17. 17. Evans N. Preterm patent ductus arteriosus: should we treat it? J Paediatr and Child Health. 2012;48:753-8. doi: 10.1111/j.1440-1754.2012.02542.x.10.1111/j.1440-1754.2012.02542.x22970669
  18. 18. Meyer S. PDA in neonates—please doctor act individually! Acta Paediatr. 2012;101:e145-6. DOI: 10.1111/j.1651-2227.2012.02617.x.10.1111/j.1651-2227.2012.02617.x
  19. 19. Koch J, Hensley G, Roy L, Brown S, Ramaciotti C, Rosenfeld CR. Prevalence of spontaneous closure of the ductus arteriosus in neonates at a birth weight of 1000 grams or less. Pediatrics. 2006;117:1113-21. DOI: 10.1542/peds.2005-1528.10.1542/peds.2005-152816585305
  20. 20. Hamrick SE, Hansmann G. Patent ductus arteriosus of the preterm infant. Pediatrics. 2010;125:1020-30. doi: 10.1542/peds.2009-3506.10.1542/peds.2009-350620421261
  21. 21. Chen H-L, Yang R-C, Lee W-T, et al. Lung function in very preterm infants with patent ductus arteriosus under conservative management: an observational study. BMC Pediatrics. 2015;15:167. DOI: 10.1186/s12887-015-0480-y.10.1186/s12887-015-0480-y462000126496854
  22. 22. Du J-F, Liu T-T, Wu H. Risk factors for patent ductus arteriosus in early preterm infants: a case-control study. Zhongguo Dang Dai Er Ke Za Zhi. 2016;18:15-9.
  23. 23. Garcıa-Munoz RF, Galan HG, Figueras AJ, Garcıa-Alix PA. Outcomes of very-low-birth-weight infants exposed to maternal clinical chorioamnionitis: a multicentre study. Neonatology 2014;106:229-34. doi: 10.1159/000363127.10.1159/00036312725011418
  24. 24. Park HW, Choi Y-S, Kim KS, Kim S-N. Chorioamnionitis and Patent Ductus Arteriosus: A Systematic Review and Meta-Analysis. PLoS ONE. 2015;10:e0138114. doi: 10.1371/journal.pone.0138114.10.1371/journal.pone.0138114457416726375582
  25. 25. Gonzalez A, Sosenko IR, Chandar J, et al. Influence of infection on patent ductus arteriosus and chronic lung disease in premature infants weighing 1000 grams or less. J Pediatr. 1996;128:470-8.10.1016/S0022-3476(96)70356-6
  26. 26. Seppanen MP, Ojanpera OS, Kaapa PO, Kero PO. Delayed postnatal adaptation of pulmonary hemodynamics in infants of diabetic mothers. J Pediatr. 1997;131:545-8.10.1016/S0022-3476(97)70059-3
  27. 27. Rakza T, Magnenant E, Klosowski S, Tourneux P, Bachiri A, Storme L. Early hemodynamic consequences of patent ductus arteriosus in preterm infants with intrauterine growth restriction. J Pediatr. 2007;151:624-8. DOI: 10.1016/j.jpeds.2007.04.058.10.1016/j.jpeds.2007.04.058
  28. 28. Agarwal R, Deorari AA, Paul VK. Patent Ductus Arteriosus in Preterm Neonates. Indian J Pediatr. 2008;75:277. doi: 10.1007/s12098-008-0059-9.10.1007/s12098-008-0059-9
  29. 29. Saeidi R, Mahmoodi E, Eslami M, Gholami M. Evaluation of Risk Factors Related with Neonatal Patent Ductus Arteriosus in Hospitalized Neonates of Neonatal Intensive Care Unit. Zahedan J Res Med Sci (ZJRMS). 2012;14:33-5.
  30. 30. Bell EF, Acarregui MJ. Restricted versus liberal water intake for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev. 2008;(1):CD000503. doi: 10.1002/14651858.CD000503.pub2.10.1002/14651858.CD000503.pub2
  31. 31. Green TP, Thompson TR, Johnson DE, Lock JE. Furosemide promotes patent ductus arteriosus in premature infants with the respiratory distress syndrome. N Engl J Med. 1983;308:743-8.10.1056/NEJM198303313081303
  32. 32. Simon SR, van Zogchel L, Bas-Suárez MP, Cavallaro G, Clyman RI, Villamor E. Platelet Counts and Patent Ductus Arteriosus in Preterm Infants: A Systematic Review and Meta-Analysis. Neonatology. 2015;108:143-51. doi: 10.1159/000431281.10.1159/000431281
  33. 33. Shimada S, Kasai T, Hoshi A, Murata A, Chida S. Cardiocirculatory effects of patent ductus arteriosus in extremely low-birth-weight infants with respiratory distress syndrome. Pediatr Int. 2003;45:255-62.10.1046/j.1442-200X.2003.01713.x
  34. 34. Noori S, Patel D, Friedlich P, Siassi B, Seri I, Ramanathan R. Effects of low oxygen saturation limits on the ductus arteriosus in extremely low birth weight infants. J Perinatol. 2009;29:553-7. doi: 10.1038/jp.2009.60.10.1038/jp.2009.60
  35. 35. Kaapa P, Seppanen M, Kero P, Saraste M. Pulmonary hemodynamics after synthetic surfactant replacement in neonatal respiratory distress syndrome. J Pediatr. 1993;123:115-9.10.1016/S0022-3476(05)81553-7
  36. 36. Soll R, Özek E. Prophylactic protein free synthetic surfactant for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev. 2010;(1):CD001079. doi: 10.1002/14651858.CD001079.pub2.10.1002/14651858.CD001079.pub2705918120091513
  37. 37. Rosenfeld W, Sadhev S, Brunot V, Jhaveri R, Zabaleta I, Evans HE. Phototherapy effect on the incidence of patent ductus arteriosus in premature infants: prevention with chest shielding. Pediatrics. 1986;78:10-4.10.1542/peds.78.1.10
  38. 38. Sadecka LSR, Leoneb CR, Procianoyc RS, et al. Effects of therapeutic approach on the neonatal evolution of very low birth weight infants with patent ductus arteriosus. J Pediatr (Rio J). 2014;90:616-23. doi: 10.1016/j.jped.2014.04.010.10.1016/j.jped.2014.04.01025046256
  39. 39. Hajjar ME, Vaksmann G, Rakza T, Kongolo G, Storme L. Severity of the ductal shunt: a comparison of different markers. Arch Dis Child Fetal Neonatal Ed. 2005;90:F419-22. DOI: 10.1136/adc.2003.027698.10.1136/adc.2003.027698172194416113155
  40. 40. Kluckow M, Evans N. Ductal shunting, high pulmonary blood flow, and pulmonary hemorrhage. J Pediatr. 2000;137:68-72.10.1067/mpd.2000.10656910891824
  41. 41. Mosalli R, Alfaleh K. Prophylactic surgical ligation of patent ductus arteriosus for prevention of mortality and morbidity in extremely low birth weight infants. Cochrane Database Syst Rev. 2008;(1):CD006181. doi: 10.1002/14651858.CD006181.pub2.10.1002/14651858.CD006181.pub2891621818254095
  42. 42. Noori S. Patent ductus arteriosus in the preterm infant: to treat or not to treat? J Perinatol. 2010;30 Suppl:S31-7. doi: 10.1038/jp.2010.97.10.1038/jp.2010.9720877405
  43. 43. Dollberg S, Lusky A, Reichman B. Patent ductus arteriosus, indomethacin and necrotizing enterocolitis in very low birth weight infants: a population-based study. J Pediatr Gastroenterol Nutr. 2005;40:184-8.10.1097/00005176-200502000-0001915699694
  44. 44. McPherson C, Gal P, Smith M, et al. Necrotizing Entrocolitis and Intestinal Perforation in Preterm Infants with Patent Ductus Arteriosus: Does indomethacin increase the risk? Journal of Neonatal-Perinatal Medicine. 2008;1:209-16.
  45. 45. Sellmer A, Bjerre JV, Schmidt MR, et al. Morbidity and mortality in preterm neonates with patent ductus arteriosus on day 3. Arch Dis Child Fetal Neonatal Ed. 2013;98:F505-10. doi: 10.1136/archdischild-2013-303816.10.1136/archdischild-2013-30381623893268
  46. 46. Evans N, Kluckow M. Early ductal shunting and intraventricular haemorrhage in ventilated preterm infants. Arch Dis Child Fetal Neonatal Ed. 1996;75:F183-6.10.1136/fn.75.3.F183
  47. 47. Noori S, McCoy M, Friedlich P, et al. Failure of ductus arteriosus closure is associated with increased mortality in preterm infants. Pediatrics. 2009;123:e138-44. doi: 10.1542/peds.2008-2418.10.1542/peds.2008-2418
  48. 48. Benitz WE. Treatment of persistent patent ductus arteriosus in preterm infants: time to accept the null hypothesis? J Perinatol. 2010;30:241-52. doi: 10.1038/jp.2010.3.10.1038/jp.2010.3
  49. 49. Clyman RI, Couto J, Murphy GM. Patent ductus arteriosus: are current neonatal treatment options better or worse than no treatment at all? Semin Perinatol. 2012;36:123-9. doi: 10.1053/j.semperi.2011.09.022.10.1053/j.semperi.2011.09.022
  50. 50. Ivey KN, Srivastava D. The paradoxical patent ductus arteriosus. J Clin Invest. 2006;116:2863-5. Doi: 10.1172/JCI30349.10.1172/JCI30349
  51. 51. Vermont-Oxford trials network database project. Manual of Operations, Release 2.0. Neonatal Research and Technology Assessment, Inc. Burlington, 1993.
  52. 52. Nemerofsky SL, Parravicini E, Bateman D, Kleinman C, Polin RA, Lorenz JM. The ductus arteriosus rarely requires treatment in infants > 1000 grams. Am J Perinatol. 2008;25:661-6. doi: 10.1055/s-0028-1090594.10.1055/s-0028-1090594
  53. 53. Fanaroff AA, Hack M, Walsh MC. The NICHD Neonatal Research Network: changes in practice and outcomes during the first 15 years. Semin Perinatol. 2003;27:281-7.10.1016/S0146-0005(03)00055-7
  54. 54. Popat H, Kapoor V, Travadi J. Patent Ductus Arteriosus in Infants <29 Weeks Gestation –Outcomes and Factors Affecting Closure. Indian Pediatr. 2012;49:615-20.10.1007/s13312-012-0132-322317982
  55. 55. Eronen M, Kari A, Pesonen E, Hallman M. The effect of antenatal dexamethazone administration on the fetal and neonatal ductus arteriosus. A randomized double-blind study. Am J Dis Child. 1993;147:187-92.10.1001/archpedi.1993.021602600770268427243
  56. 56. Halliday HL, Ehrenkranz RA, Doyle LW. Early (< 8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev. 2009;(1):CD001146. doi: 10.1002/14651858.CD001146.pub2.10.1002/14651858.CD001146.pub219160190
  57. 57. Kim ES, Kim EK, Choi CW, et al. Intrauterine inflammation as a risk factor for persistent ductus arteriosus patency after cyclooxygenase inhibition in extremely low birth weight infants. J Pediatr. 2010;157:745-50.e1. doi: 10.1016/j.jpeds.2010.05.020.10.1016/j.jpeds.2010.05.02020598319
  58. 58. Shah DM, Shenai JP, Vaughn WK. Neonatal outcome of premature infants of mothers with preeclampsia. J Perinatol. 1995;15:264-7.
  59. 59. Tsai M-L, Lien R, Chiang M-C, et al. Prevalence and Morbidity of Late Preterm Infants: Current Status in a Medical Center of Northern Taiwan. Pediatr Neonatol. 2012;53:171-7. doi: 10.1016/j.pedneo.2012.04.003.10.1016/j.pedneo.2012.04.00322770105
  60. 60. Ognean ML, Stoicescu SM, Boanta O, Nastase L, Gliga C, Cucerea M. Intubation-Surfactant: Extubation on Continuous Positive Pressure Ventilation. Who are the best candidates? J Crit Care Med. 2016;2:73-9. DOI: 10.1515/jccm-2016-0010.10.1515/jccm-2016-0010593913029967841
  61. 61. Pegoli W. Pericardium and great vessels. In: Oldham KT, Colombiani PM, et al. (eds). Principles and Practice of Pediatric Surgery. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins 2005; 1019.
  62. 62. Smith GC. The pharmacology of the ductus arteriosus. Pharmacol Rev. 1998;50:35-58.
  63. 63. Sweet Dg, Carnielli V, Greisen G, et al. European consensus guidelines on the management of neonatal respiratory distress syndrome in preterm infants--2013 update. Neonatology. 2013;103:353-68. doi: 10.1159/000349928.10.1159/00034992823736015
  64. 64. Tauzin L, Joubert C, Noel A-C, Bouissou A, Moulies M-E. Effect of persistent patent ductus arteriosus on mortality and morbidity in very low-birthweight infants. Acta Paediatr. 2012;101:419-23. doi: 10.1111/j.1651-2227.2011.02550.x.10.1111/j.1651-2227.2011.02550.x22133090
  65. 65. Ferreira CH, Carmona F, Martinez FE. Prevalence, risk factors and outcomes associated with pulmonary hemorrhage in newborns. J Pediatr (Rio J). 2014;90:316-22. doi: 10.1016/j.jped.2013.12.008.10.1016/j.jped.2013.12.00824606947
  66. 66. Zahr RA, Marron-Corwin M. Neonatal pulmonary hemorrhage. NeoReviews 2012;13:e302-6. doi: 10.1542/neo.13-5-e302.10.1542/neo.13-5-e302
  67. 67. Stucin Gantar I, Babnik J, Kornhauser Cerar L, Sinkovec J, Wraber B. Prenatal and postnatal risk factors for developing bronchopulmonary dysplasia. Signa Vitae. 2011;6:46-51.10.22514/SV62.102011.6
  68. 68. Ohlsson A, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev. 2013;(4):CD003481. doi: 10.1002/14651858.CD003481.pub5.10.1002/14651858.CD003481.pub523633310
  69. 69. Benitz WE. Patent ductus arteriosus: to treat or not to treat? Arch Dis Child Fetal Neonatal Ed. 2012;97:F80-2. doi: 10.1136/archdischild-2011-300381.10.1136/archdischild-2011-30038122174019
  70. 70. Marshall DD, Kotelchuck M, Young TE, Bose CL, Kruyer L, O’Shea TM. Risk factors for chronic lung disease in the surfactant era: a North Carolina population-based study of very low birth weight infants. North Carolina Neonatologists Association. Pediatrics. 1999;104:1345-50.10.1542/peds.104.6.134510585987
  71. 71. Noerr B. Current controversies in the understanding of necrotizing enterocolitis Part 1. Adv Neonatal Care. 2003;3:107-20.
  72. 72. Shortland DB, Gibson NA, Levene MI, Archer LNJ, Evans DH, Shaw DE. Patent ductus arteriosus and cerebral circulation in preterm infants. Dev Med Child Neurol. 1990;32:386-93.10.1111/j.1469-8749.1990.tb16957.x2354752
  73. 73. Ibrahim TK, Haium AAA, Chandran S, Rajadurai VS. Current Controversies in the Management of Patent Ductus Arteriosus in Preterm Infants. Indian Pediatr. 2014;51:289-94.10.1007/s13312-014-0403-224825266
DOI: https://doi.org/10.1515/jccm-2016-0026 | Journal eISSN: 2393-1817 | Journal ISSN: 2393-1809
Language: English
Page range: 175 - 184
Submitted on: Aug 10, 2016
Accepted on: Sep 15, 2016
Published on: Nov 8, 2016
Published by: University of Medicine, Pharmacy, Science and Technology of Targu Mures
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2016 Maria Livia Ognean, Oana Boantă, Simona Kovacs, Corina Zgârcea, Raluca Dumitra, Ecaterina Olariu, Doina Andreicuţ, published by University of Medicine, Pharmacy, Science and Technology of Targu Mures
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.